z-logo
Premium
Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12
Author(s) -
Micheletti R.G.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18437
Subject(s) - hidradenitis suppurativa , adalimumab , medicine , dermatology , disease
Linked Article:   Jemec et al . Br J Dermatol 2019; 181 :967–975.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom